Drug regulators in China are focusing on approving homegrown antiviral therapies with the ability to tackle new COVID-19 variants, according to analysis from a data and analytics provider.
The findings have been presented following Chinese regulator the National Medical Products Administration’s (NMPA) conditional approval of two homegrown oral drugs, Simcere Pharmaceutical’s (HKG: 2096) Xiannuoxin (simnotrelvir/ritonavir) and Shanghai Junshi Biosciences' (SHA: 688180) Mindevir (Deuterium remidevir tablets) for the treatment of mild to moderate COVID-19.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze